SQZ Biotechnologies Company (SQZ)
| Market Cap | 620.64M |
| Revenue (ttm) | 22.82M |
| Net Income (ttm) | -38.71M |
| Shares Out | 23.97M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $24.24 |
| Previous Close | $26.17 |
| Change ($) | -1.93 |
| Change (%) | -7.37% |
| Day's Open | 26.00 |
| Day's Range | 24.01 - 26.00 |
| Day's Volume | 24,635 |
| 52-Week Range | 13.25 - 34.58 |
News
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, ch...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public of...
About SQZ
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional p... [Read more...]
| Industry Biotechnology | IPO Date Oct 30, 2020 |
| CEO Armon Sharei | Employees 101 |
| Stock Exchange NYSE | Ticker Symbol SQZ |
Financial Performance
In 2019, SQZ's revenue was $20.11 million, an increase of 58.73% compared to the previous year's $12.67 million. Losses were -$32.20 million, 67.3% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 38.33, which is an increase of 58.13% from the latest price.